Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma

Cancer Res Treat. 2018 Jul;50(3):646-657. doi: 10.4143/crt.2016.550. Epub 2017 Jul 17.

Abstract

Purpose: Early prediction of treatment outcomes represents an essential step towards increased treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study, we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify biomarkers predictive of therapeutic outcomes in patients with HCC who received liver-directed therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mechanisms of the identified proteins.

Materials and methods: 2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis; serum proteomic profiles of the two groups were compared and analyzed using matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after overexpression and knockdown of target protein in Huh7 cells.

Results: Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex, carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher in patients with a good prognosis, compared to patients with a poor prognosis. The migration ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression and knockdown, respectively. The tumors of patients with HCC and a good prognosis expressed high levels of ITIH4, compared to those of patients with a poor prognosis.

Conclusion: Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metastasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.

Keywords: Biomarkers; Hepatocellular carcinoma; ITIH4; Liver-directed therapy; Prognosis.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Blood Proteins
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / therapy*
  • Cell Line, Tumor
  • Cell Movement
  • Chemoradiotherapy
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / therapeutic use
  • Gene Expression Regulation, Neoplastic
  • Glycoproteins / blood*
  • Humans
  • Infusions, Intra-Arterial
  • Liver Neoplasms / blood
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Proteinase Inhibitory Proteins, Secretory / blood*
  • Proteomics / methods*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Survival Analysis
  • Treatment Outcome
  • Up-Regulation

Substances

  • Biomarkers, Tumor
  • Blood Proteins
  • Glycoproteins
  • ITIH4 protein, human
  • Proteinase Inhibitory Proteins, Secretory
  • Fluorouracil